Skip to content
10-Q

Quarterly Report

ABVC BioPharma, Inc. ABVC

0001213900-25-075644

← back to feed
Filed
Aug 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 12, 2025 23.54M sh
Shares Diluted Q2 2025 · Jun 30, 2025 17.39M sh
Shares Diluted Q2 2025 · Jun 30, 2025 16.18M sh
Shares Diluted Q2 2025 · Jun 30, 2024 11.32M sh
Shares Diluted restated Q2 2025 · Jun 30, 2024 10.59M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$1.43M
Operating Cash Flow restated Q2 2025 · Jun 30, 2024 −$1.17M
Short Term Debt Q2 2025 · Jun 30, 2025 $871.95K
Short Term Debt Q2 2025 · Dec 31, 2024 $840.25K
Short Term Investments Q2 2025 · Jun 30, 2025 $65.21K
Short Term Investments Q2 2025 · Dec 31, 2024 $64.74K
Cash And Equivalents Q2 2025 · Jun 30, 2025 $388.25K
Cash And Equivalents Q2 2025 · Dec 31, 2024 $248.38K
Stockholders Equity Q2 2025 · Jun 30, 2025 $7.01M
Stockholders Equity Q2 2025 · Dec 31, 2024 $1.23M
Stockholders Equity restated Q2 2025 · Jun 30, 2024 $1.79M
Current Liabilities Q2 2025 · Jun 30, 2025 $6.53M
Current Liabilities Q2 2025 · Dec 31, 2024 $6.56M
Current Liabilities restated Q2 2025 · Jun 30, 2024 $6.25M
Total Liabilities Q2 2025 · Jun 30, 2025 $6.75M
Total Liabilities Q2 2025 · Dec 31, 2024 $6.82M
Total Liabilities restated Q2 2025 · Jun 30, 2024 $6.5M
Current Assets Q2 2025 · Jun 30, 2025 $2.77M
Current Assets Q2 2025 · Dec 31, 2024 $2.18M
Current Assets restated Q2 2025 · Jun 30, 2024 $2.31M
Total Assets Q2 2025 · Jun 30, 2025 $16.24M
Total Assets Q2 2025 · Dec 31, 2024 $7.54M
Total Assets restated Q2 2025 · Jun 30, 2024 $8.04M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.13
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.19
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$0.08
Eps Diluted restated Q2 2025 · Jun 30, 2024 −$0.36
Eps Basic Q2 2025 · Jun 30, 2025 −$0.13
Eps Basic Q2 2025 · Jun 30, 2025 −$0.19
Eps Basic restated Q2 2025 · Jun 30, 2024 −$0.08
Eps Basic restated Q2 2025 · Jun 30, 2024 −$0.36
Sga Expense Q2 2025 · Jun 30, 2025 $690.09K
Sga Expense Q2 2025 · Jun 30, 2025 $1.31M
Sga Expense restated Q2 2025 · Jun 30, 2024 $653.78K
Sga Expense restated Q2 2025 · Jun 30, 2024 $1.39M
Rd Expense Q2 2025 · Jun 30, 2025 $33.28K
Rd Expense Q2 2025 · Jun 30, 2025 $62.14K
Rd Expense Q2 2025 · Jun 30, 2024 $40.4K
Rd Expense Q2 2025 · Jun 30, 2024 $109.47K
Net Income Q2 2025 · Jun 30, 2025 −$2.26M
Net Income Q2 2025 · Jun 30, 2025 −$3.1M
Net Income Q2 2025 · Jun 30, 2024 −$942.34K
Net Income Q2 2025 · Jun 30, 2024 −$3.78M
Operating Income Q2 2025 · Jun 30, 2025 −$2.29M
Operating Income Q2 2025 · Jun 30, 2025 −$2.99M
Operating Income restated Q2 2025 · Jun 30, 2024 −$860.11K
Operating Income restated Q2 2025 · Jun 30, 2024 −$3.7M
Gross Profit Q2 2025 · Jun 30, 2024 $116.95K
Gross Profit Q2 2025 · Jun 30, 2024 $117.88K
Cost Of Revenue Q2 2025 · Jun 30, 2024 $190
Cost Of Revenue Q2 2025 · Jun 30, 2024 $467
Revenue Q2 2025 · Jun 30, 2024 $117.14K
Revenue Q2 2025 · Jun 30, 2024 $118.35K